Johnson & Johnson改变340B定价, 要求比例过高的医院为Stellara和Xarelto支付全额费用, Johnson & Johnson changes 340B pricing, requiring disproportionate share hospitals to pay full price for Stelara and Xarelto, with critics claiming it violates federal law and increases hospital costs.

Johnson & Johnson(J&J)将于10月15日实施340B定价的新政策, 要求比例过高的医院以全额价格购买药品Stelana和Xarelto, 并提交数据以换取回扣。 Johnson & Johnson (J&J) will implement a new policy for 340B pricing on October 15, requiring disproportionate share hospitals to purchase drugs Stelara and Xarelto at full price and submit data for a rebate. 包括340B卫生医院游说团和HRSA在内的批评者称,这一行动违反了联邦法律,增加了医院费用,可能导致安全网设施关闭。 Critics, including the 340B Health hospital lobby and HRSA, claim this move violates federal law and increases costs for hospitals, possibly leading to closures for safety-net facilities. J&J为这项改革辩护,以努力改善340B方案的完整性。 J&J defends the change as an effort to improve the 340B program's integrity.